Connor, Clark & Lunn Investment Management (CC&L)
IMDZ

Connor, Clark & Lunn Investment Management (CC&L)’s Immune Design Corp. IMDZ Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio IMDZ Stock Details IMDZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-31,855
Closed -$330K – 922
2017
Q3 		$330K Buy
31,855
+5,225
+20% +$51.4K ﹤0.01% 696
2017
Q2 		$260K Buy
26,630
+14,330
+117% +$101K ﹤0.01% 699
2017
Q1 		$84K Buy
+12,300
New +$71.1K ﹤0.01% 857

Other funds holding IMDZ

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s IMDZ Position: Q4 2017 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Immune Design Corp. (IMDZ) in Q4 2017, closing a stake of 31,855 shares — an estimated $330K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in IMDZ in Q1 2017 and held it in 3 quarters. The position peaked at $330K in Q3 2017. 76 funds tracked by Wall St. Rank hold IMDZ as of Q4 2017.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Immune Design Corp. position as of Q4 2017 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 31,855 Immune Design Corp. shares in Q4 2017, an estimated $330K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Immune Design Corp. in Q1 2017 and held it in 3 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Immune Design Corp. position peaked at $330K in Q3 2017.
  • 76 funds tracked by Wall St. Rank held Immune Design Corp. as of Q4 2017.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q4 2017, filed 9 Feb 2018.